MALARIA VACCINE

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

12793575

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites. The difference was most pronounced for the MSP3-specific antibody response suggesting that T cell epitopes located in the GLURP RO-region provide help for B-cell epitopes in the MSP3 region. Moreover, when the animals were injected with a mixture of GLURP and MSP3, individual mice tended to mount a predominant antibody response against either molecule: in some animals GLURP was immunodominant whereas in other animals MSP3 was the dominant immunogen. Additionally, the hybrid was also more antigenic than the individual recombinant proteins since the ELISA-titer of naturally occurring IgG antibodies, in clinically

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
STATENS SERUM INSTITUTARTILLERIVEJ 5 COPENHAGEN S DK-2300

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
JEPSEN, SØREN HOLTE, DK 2 0
THEISEN, MICHAEL FREDERIKSBERG C, DK 10 43

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation